All In Biotech

Drug Trial Radar · NCT00559988

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

The IMPACT of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients With ICD and CRT-D Devices

Last checked: Nov 19, 2026Latest source record: Dec 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 2,718 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,718

Actual

Start

Feb 2008

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Biotronik, Inc.Industry
Sponsor type
Industry
First posted
Nov 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and physician-directed anticoagulation in patients with implanted dual-chamber defibrillators or cardiac resynchronization therapy devices.

Conditions

  • Atrial Fibrillation
  • Atrial Flutter
  • Stroke
  • Embolism, Systemic Arterial
  • Major Bleeding

Interventions

  • Home Monitoring Guided OACDrug

    Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy. OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA

  • Physician-Directed OACDrug

    Patients will receive physician-directed anticoagulation therapy based on conventional criteria. OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Primary Endpoint: Kaplan-Meier Estimate of Patients Without a Stroke, Systemic Embolism, or Major BleedTime frame: From date of enrollment until date of primary endpoint event, assessed up to study exit, with a mean treatment duration of 2.0 years

Locations

80 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Fremont, California

  • Site not named

    Santa Barbara, California

  • Site not named

    Torrance, California

  • Site not named

    Ventura, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Boulder, Colorado

  • Site not named

    Newark, Delaware

  • Site not named

    Davenport, Florida

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Kissimmee, Florida

  • Site not named

    Melbourne, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Elk Grove Village, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Shawnee Mission, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Hammond, Louisiana

  • Site not named

    Lafayette, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Bangor, Maine

  • Site not named

    Lewiston, Maine

  • Site not named

    Cumberland, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Burlington, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Bay City, Michigan

  • Site not named

    Lansing, Michigan

  • Site not named

    Lapeer, Michigan

  • Site not named

    Saginaw, Michigan

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.